JP2004524368A - 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 - Google Patents
低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 Download PDFInfo
- Publication number
- JP2004524368A JP2004524368A JP2002578922A JP2002578922A JP2004524368A JP 2004524368 A JP2004524368 A JP 2004524368A JP 2002578922 A JP2002578922 A JP 2002578922A JP 2002578922 A JP2002578922 A JP 2002578922A JP 2004524368 A JP2004524368 A JP 2004524368A
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- container
- suspension
- lipid particles
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 30
- 230000003381 solubilizing effect Effects 0.000 title description 5
- 150000002632 lipids Chemical class 0.000 claims abstract description 147
- 239000002245 particle Substances 0.000 claims abstract description 75
- 150000002634 lipophilic molecules Chemical class 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 239000007900 aqueous suspension Substances 0.000 claims abstract description 7
- 239000000725 suspension Substances 0.000 claims description 51
- 150000003904 phospholipids Chemical class 0.000 claims description 33
- 239000012528 membrane Substances 0.000 claims description 27
- 239000006185 dispersion Substances 0.000 claims description 23
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- -1 2-amino-1-ethyl Chemical group 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 230000005540 biological transmission Effects 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 239000012736 aqueous medium Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000003833 bile salt Substances 0.000 claims description 5
- 229930186217 Glycolipid Natural products 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 102100037611 Lysophospholipase Human genes 0.000 claims description 3
- 108010058864 Phospholipases A2 Proteins 0.000 claims description 3
- 229940106189 ceramide Drugs 0.000 claims description 3
- 150000001783 ceramides Chemical class 0.000 claims description 3
- 229930183167 cerebroside Natural products 0.000 claims description 3
- 150000001784 cerebrosides Chemical class 0.000 claims description 3
- 150000002270 gangliosides Chemical class 0.000 claims description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- NPLMVGGTFDUQHL-OUKQBFOZSA-N 2-[(e)-octadec-9-enoxy]ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCC\C=C\CCCCCCCCOCCOP([O-])(=O)OCC[N+](C)(C)C NPLMVGGTFDUQHL-OUKQBFOZSA-N 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 1
- 238000011068 loading method Methods 0.000 abstract description 21
- 239000000243 solution Substances 0.000 abstract description 18
- 238000011065 in-situ storage Methods 0.000 abstract description 14
- 238000002347 injection Methods 0.000 abstract description 8
- 239000007924 injection Substances 0.000 abstract description 8
- 239000008176 lyophilized powder Substances 0.000 abstract description 4
- 238000013019 agitation Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 39
- 239000003814 drug Substances 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 239000002502 liposome Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 238000003860 storage Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 9
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 9
- 239000013583 drug formulation Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 6
- 108010036949 Cyclosporine Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229960001265 ciclosporin Drugs 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 239000007972 injectable composition Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004931 aggregating effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- PAZGBAOHGQRCBP-DDDNOICHSA-N 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-DDDNOICHSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- MRABAEUHTLLEML-UHFFFAOYSA-N Butyl lactate Chemical compound CCCCOC(=O)C(C)O MRABAEUHTLLEML-UHFFFAOYSA-N 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- 101000807541 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 24 Proteins 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 102100037176 Ubiquitin carboxyl-terminal hydrolase 24 Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 description 1
- JABXMSSGPHGCII-UHFFFAOYSA-N acetic acid;propane-1,2-diol Chemical compound CC(O)=O.CC(O)CO JABXMSSGPHGCII-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001191 butyl (2R)-2-hydroxypropanoate Substances 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229940113125 polyethylene glycol 3000 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229960000323 triclabendazole Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01302841 | 2001-03-27 | ||
| PCT/EP2002/003371 WO2002080883A2 (en) | 2001-03-27 | 2002-03-26 | Method and composition for solubilising a biologically active compound with low water solubility |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009199056A Division JP2010013461A (ja) | 2001-03-27 | 2009-08-28 | 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004524368A true JP2004524368A (ja) | 2004-08-12 |
| JP2004524368A5 JP2004524368A5 (enExample) | 2005-06-09 |
Family
ID=8181836
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002578922A Withdrawn JP2004524368A (ja) | 2001-03-27 | 2002-03-26 | 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 |
| JP2009199056A Pending JP2010013461A (ja) | 2001-03-27 | 2009-08-28 | 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 |
| JP2012163789A Pending JP2012207042A (ja) | 2001-03-27 | 2012-07-24 | 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009199056A Pending JP2010013461A (ja) | 2001-03-27 | 2009-08-28 | 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 |
| JP2012163789A Pending JP2012207042A (ja) | 2001-03-27 | 2012-07-24 | 低い水溶性を有する生物学的に活性な化合物を可溶化するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20040115255A1 (enExample) |
| EP (1) | EP1389089B1 (enExample) |
| JP (3) | JP2004524368A (enExample) |
| AT (1) | ATE440593T1 (enExample) |
| AU (1) | AU2002312777B2 (enExample) |
| CA (1) | CA2442539C (enExample) |
| DE (1) | DE60233484D1 (enExample) |
| DK (1) | DK1389089T3 (enExample) |
| ES (1) | ES2332584T3 (enExample) |
| PT (1) | PT1389089E (enExample) |
| WO (1) | WO2002080883A2 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006098241A1 (ja) * | 2005-03-14 | 2006-09-21 | Otsuka Pharmaceutical Factory, Inc. | 難水溶性薬物を含有する医薬組成物 |
| JP2007507432A (ja) * | 2003-10-02 | 2007-03-29 | セムバイオシス ジェネティクス インコーポレイテッド | 活性成分を含む油体を調製するための方法 |
| JP2013536805A (ja) * | 2010-09-01 | 2013-09-26 | 北京大学 | 難溶性薬物の液体組成物及びその調製方法 |
| JP2016190881A (ja) * | 2008-05-23 | 2016-11-10 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | リポソームナノ粒子中で使用するための修飾薬物 |
| JP2017048188A (ja) * | 2008-09-27 | 2017-03-09 | ジャイナ ファーマシューティカルズ，インコーポレーテッド | 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用 |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7444383B2 (en) | 2000-06-17 | 2008-10-28 | Microsoft Corporation | Bounded-deferral policies for guiding the timing of alerting, interaction and communications using local sensory information |
| US6951656B2 (en) | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US6884436B2 (en) | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
| US6977085B2 (en) | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
| US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
| US7193084B2 (en) | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
| US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
| US6607784B2 (en) | 2000-12-22 | 2003-08-19 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| AU2002337692B2 (en) | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| DE10203923B4 (de) * | 2002-01-31 | 2011-06-01 | Klinipharm Gmbh | Verfahren zur Erhöhung der Wasserlöslichkeit lipophiler Wirkstoffe, Herstellung von hochkonzentrierten wässrigen Zusammensetzungen dieser Wirkstoffe, derartige Produkte und ihre Verwendung |
| WO2005065677A1 (ja) * | 2004-01-09 | 2005-07-21 | Otsuka Pharmaceutical Factory, Inc. | パクリタキセルまたはドセタキセルを溶解または分散させるための脂肪乳剤 |
| US7345093B2 (en) | 2004-04-27 | 2008-03-18 | Formatech, Inc. | Methods of enhancing solubility of compounds |
| US7659310B2 (en) | 2004-04-27 | 2010-02-09 | Formatech, Inc. | Methods of enhancing solubility of agents |
| DK1748759T3 (da) * | 2004-04-27 | 2013-04-22 | Javeri Indu | Fremgangsmåder til at forøge hydrofobe forbindelsers opløselighed i vand af ved micellære dispersioner |
| US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
| ES2372499T3 (es) | 2004-05-19 | 2012-01-20 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Uso de un detergente para la eliminación no quirúrgica de grasa. |
| US20060127468A1 (en) | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
| EP1809254A2 (en) * | 2004-10-28 | 2007-07-25 | Alza Corporation | Lyophilized liposome formulations and method |
| JP5342834B2 (ja) * | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
| US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
| WO2011038068A1 (en) | 2009-09-23 | 2011-03-31 | Formatech, Inc. | Methods for the preparation of liposomes |
| US20170340563A1 (en) * | 2009-09-23 | 2017-11-30 | Curirx Inc. | Methods for the Preparation of Liposomes Comprising Drugs |
| BR112013014291A2 (pt) * | 2010-12-08 | 2016-09-20 | Hoffmann La Roche | formulação lipossômica de calcetrapib |
| CA2827643C (en) | 2011-02-18 | 2019-05-07 | Kythera Biopharmaceuticals, Inc. | Treatment of submental fat |
| US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
| WO2013176223A1 (ja) * | 2012-05-23 | 2013-11-28 | 国立大学法人大阪大学 | 炎症性疾患治療用医薬組成物 |
| EP2682106A1 (en) | 2012-07-03 | 2014-01-08 | Phares Pharmaceutical Research N.V. | Method of solubilizing biologically active compounds |
| IL259246B2 (en) | 2015-12-07 | 2024-11-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Compositions for oral administration comprising at least one cannabinoid, a method for the preparation thereof and use of same |
| IL266198B2 (en) | 2016-10-28 | 2023-11-01 | Servier Lab | Liposomal formulation for use in cancer treatment |
| CA3063395A1 (en) * | 2017-05-12 | 2018-11-15 | Curinanorx, Llc | Methods for the preparation of liposomes comprising drugs |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1202370B (it) * | 1976-07-12 | 1989-02-09 | Hoffmann La Roche | Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti |
| EP0158441B2 (en) * | 1984-03-08 | 2001-04-04 | Phares Pharmaceutical Research N.V. | Liposome-forming composition |
| MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
| CA1338702C (en) * | 1987-03-05 | 1996-11-12 | Lawrence D. Mayer | High drug:lipid formulations of liposomal- antineoplastic agents |
| US5811119A (en) * | 1987-05-19 | 1998-09-22 | Board Of Regents, The University Of Texas | Formulation and use of carotenoids in treatment of cancer |
| WO1989002265A1 (fr) * | 1987-09-07 | 1989-03-23 | Teijin Limited | Emulsion grasse contenant un medicament, du type prepare immediatement avant l'utilisation, et procede de preparation d'une telle emulsion grasse contenant un medicament |
| IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5741513A (en) * | 1990-02-08 | 1998-04-21 | A. Natterman & Cie. Gmbh | Alcoholic aqueous gel-like phospholipid composition, its use and topical preparations containing it |
| US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| JP3533215B2 (ja) * | 1990-07-31 | 2004-05-31 | ザ リポソーム カンパニー，インコーポレイテッド | アミノ酸及びペプチドのリポソーム内への蓄積 |
| US5763413A (en) * | 1993-03-04 | 1998-06-09 | Mect Corporation | Lewis-associated compound, process for producing the same, and anti-inflammatory |
| DE19609538A1 (de) * | 1996-03-11 | 1997-09-18 | Basf Ag | Feinverteilte Carotinoid- und Retinoidsuspensionen und Verfahren zu ihrer Herstellung |
| DE69429511T2 (de) * | 1993-05-21 | 2002-05-16 | The Liposome Co., Inc. | Reduzierung von durch liposome induzierte physiologischen gegenreaktionen |
| EP0633024A1 (en) * | 1993-07-09 | 1995-01-11 | Ciba-Geigy Ag | Topically administrable zinc phthalocyanine compositions |
| US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| DE69503629T2 (de) * | 1994-05-23 | 1998-11-26 | B. Braun Medical Inc., Bethlehem, Pa. 18018 | Vorrichtung zur herstellung einer formulierung |
| JP2740153B2 (ja) * | 1995-03-07 | 1998-04-15 | エフ・ホフマン−ラ ロシユ アーゲー | 混合ミセル |
| US6447800B2 (en) * | 1996-01-18 | 2002-09-10 | The University Of British Columbia | Method of loading preformed liposomes using ethanol |
| US6096336A (en) * | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
| US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| EP0974364A4 (en) * | 1996-10-25 | 2000-12-20 | Yoshitomi Pharmaceutical | METHOD FOR PREVENTING THE PREPARATION OF MEDICINAL PRODUCTS |
| ES2200144T3 (es) * | 1996-12-13 | 2004-03-01 | Vesifact Ag | Preparaciones cosmeticas. |
| GB9726916D0 (en) * | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
| WO2000002534A1 (fr) * | 1998-07-10 | 2000-01-20 | Welfide Corporation | Kit a preparer avant usage avec preparation contenant un medicament et solvant destine a cette fin |
| DE19843968A1 (de) * | 1998-09-24 | 2000-04-13 | Hans Dietl | Taxane enthaltende pharmazeutische Zubereitung zur intravenösen Applikation und Verfahren zu ihrer Herstellung |
| US6682758B1 (en) * | 1998-12-22 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Water-insoluble drug delivery system |
| WO2000059473A1 (en) * | 1999-04-01 | 2000-10-12 | Inex Pharmaceuticals Corp. | Compositions and methods for treating lymphoma |
| US20030144570A1 (en) * | 1999-11-12 | 2003-07-31 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors |
| US20020001613A1 (en) * | 2000-02-08 | 2002-01-03 | Susan Niemiec | Method of manufacturing liposomes |
-
2002
- 2002-03-26 WO PCT/EP2002/003371 patent/WO2002080883A2/en not_active Ceased
- 2002-03-26 PT PT02737899T patent/PT1389089E/pt unknown
- 2002-03-26 CA CA2442539A patent/CA2442539C/en not_active Expired - Fee Related
- 2002-03-26 JP JP2002578922A patent/JP2004524368A/ja not_active Withdrawn
- 2002-03-26 AU AU2002312777A patent/AU2002312777B2/en not_active Ceased
- 2002-03-26 EP EP02737899A patent/EP1389089B1/en not_active Expired - Lifetime
- 2002-03-26 DE DE60233484T patent/DE60233484D1/de not_active Expired - Lifetime
- 2002-03-26 AT AT02737899T patent/ATE440593T1/de not_active IP Right Cessation
- 2002-03-26 ES ES02737899T patent/ES2332584T3/es not_active Expired - Lifetime
- 2002-03-26 DK DK02737899T patent/DK1389089T3/da active
-
2003
- 2003-09-26 US US10/670,504 patent/US20040115255A1/en not_active Abandoned
-
2008
- 2008-01-02 US US12/003,849 patent/US20080131499A1/en not_active Abandoned
-
2009
- 2009-08-28 JP JP2009199056A patent/JP2010013461A/ja active Pending
-
2012
- 2012-07-24 JP JP2012163789A patent/JP2012207042A/ja active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007507432A (ja) * | 2003-10-02 | 2007-03-29 | セムバイオシス ジェネティクス インコーポレイテッド | 活性成分を含む油体を調製するための方法 |
| WO2006098241A1 (ja) * | 2005-03-14 | 2006-09-21 | Otsuka Pharmaceutical Factory, Inc. | 難水溶性薬物を含有する医薬組成物 |
| JP4929158B2 (ja) * | 2005-03-14 | 2012-05-09 | 株式会社大塚製薬工場 | 難水溶性薬物を含有する医薬組成物 |
| KR101391020B1 (ko) * | 2005-03-14 | 2014-04-30 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 수난용성 약제를 함유한 약학 조성물 |
| JP2016190881A (ja) * | 2008-05-23 | 2016-11-10 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | リポソームナノ粒子中で使用するための修飾薬物 |
| JP2017048188A (ja) * | 2008-09-27 | 2017-03-09 | ジャイナ ファーマシューティカルズ，インコーポレーテッド | 経口適用および局所適用のための脂質系薬学的調製物、ならびにそれらの組成物、方法、および使用 |
| JP2013536805A (ja) * | 2010-09-01 | 2013-09-26 | 北京大学 | 難溶性薬物の液体組成物及びその調製方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2442539C (en) | 2011-11-08 |
| US20040115255A1 (en) | 2004-06-17 |
| CA2442539A1 (en) | 2002-10-17 |
| DK1389089T3 (da) | 2009-12-21 |
| US20080131499A1 (en) | 2008-06-05 |
| EP1389089A2 (en) | 2004-02-18 |
| PT1389089E (pt) | 2009-11-30 |
| ATE440593T1 (de) | 2009-09-15 |
| WO2002080883A2 (en) | 2002-10-17 |
| WO2002080883A3 (en) | 2003-12-11 |
| DE60233484D1 (de) | 2009-10-08 |
| JP2012207042A (ja) | 2012-10-25 |
| EP1389089B1 (en) | 2009-08-26 |
| ES2332584T3 (es) | 2010-02-09 |
| AU2002312777B2 (en) | 2007-07-05 |
| AU2002312777A2 (en) | 2002-10-21 |
| JP2010013461A (ja) | 2010-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2442539C (en) | Method and composition for solubilising a biologically active compound with low water solubility | |
| US6605298B1 (en) | Pharmaceutical compositions and their use | |
| AU2002312777A1 (en) | Method and composition for solubilising a biologically active compound with low water solubility | |
| AU731397B2 (en) | Preparation of pharmaceutical compositions | |
| JP5627039B2 (ja) | 薬物のナノ分散体およびその調製のための方法 | |
| JP2011529042A (ja) | 安定した注射可能な水中油型ドセタキセルナノエマルション | |
| JPH08268893A (ja) | スタウロスポリン誘導体の静脈内投与のための医薬組成物 | |
| JP2003526679A (ja) | 各種物質の可溶化用組成物と剤形及びそれらの製造方法 | |
| CN102740833A (zh) | 吉西他滨衍生物的肠胃外制剂 | |
| HUE027467T2 (en) | Liposomes or hydrochlorides of irinotecan and their preparation method | |
| EP3138558A1 (en) | Liposome composition and production method therefor | |
| WO2008080369A1 (fr) | Composition liposomale stable | |
| US20190105268A1 (en) | Viscoelastic Gel of Liraglutide Adapted for Once-Weekly or Once Bi-Weekly Administration | |
| WO2000061113A1 (en) | Lipid aggregate forming compositions and their uses | |
| JP2653245B2 (ja) | 脂肪乳剤 | |
| JPWO1992008467A1 (ja) | 分散製剤 | |
| JPWO1991007973A1 (ja) | 脂肪乳剤 | |
| CN112773776B (zh) | 一种载药纳米粒体系 | |
| JPH04173736A (ja) | 乳化剤 | |
| Gregory | Preparation of Liposomes and Oily Formulations by Freeze-Drying of Monophase Solutions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050318 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081114 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090220 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090306 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090430 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090828 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100107 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100312 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110726 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110729 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110830 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20120402 |